AVCO - Avalon GloboCare Corp Stock Price, Fair Value and News

0.31USD+0.03 (+10.71%)Market Closed

Market Summary

USD0.31+0.03

Market Closed

10.71%

AVCO Stock Price

View Fullscreen

AVCO RSI Chart

AVCO Valuation

Market Cap

3.4M

Price/Earnings (Trailing)

-0.21

Price/Sales (Trailing)

2.74

EV/EBITDA

-0.2

Price/Free Cashflow

-0.53

AVCO Price/Sales (Trailing)

AVCO Profitability

EBT Margin

-1316.99%

Return on Equity

-226.73%

Return on Assets

-81.17%

Free Cashflow Yield

-189.6%

AVCO Fundamentals

AVCO Revenue

Revenue (TTM)

1.3M

AVCO Earnings

Earnings (TTM)

-16.7M

Earnings Growth (Yr)

-295.22%

Earnings Growth (Qtr)

-543.41%

Breaking Down AVCO Revenue

Last 7 days

-8.8%

Last 30 days

-6.1%

Last 90 days

-18.4%

Trailing 12 Months

26.3%

How does AVCO drawdown profile look like?

AVCO Financial Health

Current Ratio

0.13

AVCO Investor Care

Shares Dilution (1Y)

9.25%

Diluted EPS (TTM)

-1.58

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2023	1.2M	1.2M	1.2M	1.3M
2022	0	0	0	1.2M
2021	4.2M	3.4M	2.7M	1.9M
2020	0	0	5.6M	4.9M
2019	4.6M	4.8M	6.0M	0
2018	1.7M	2.3M	3.0M	3.7M
2017	0	0	0	1.0M

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Avalon GloboCare Corp

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Aug 05, 2022	lu wenzhao	acquired	350,000	0.78	448,718	-
Jul 25, 2022	lu wenzhao	acquired	2,888,590	0.65	4,443,990	-
Jul 25, 2022	lu wenzhao	acquired	2,887,940	0.65	4,442,990	-
Jul 18, 2022	lu wenzhao	acquired	2,886,250	0.65	4,440,390	-
Dec 21, 2021	lu wenzhao	acquired	3,000,000	1.25	2,400,000	-
Apr 01, 2020	lu wenzhao	bought	1,000,000	1.55	645,161	-
Jun 07, 2019	lu wenzhao	bought	27,600	1.84	15,000	-
Jun 06, 2019	lu wenzhao	bought	42,630	2.03	21,000	-
Apr 18, 2019	lu wenzhao	bought	-2,000,000	1.00	-2,000,000	-
Apr 18, 2019	lu wenzhao	sold	-2,000,000	1.00	-2,000,000	-

Which funds bought or sold AVCO recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 15, 2024	Royal Bank of Canada	unchanged	-	-	-	-%
May 15, 2024	MILLENNIUM MANAGEMENT LLC	added	0.95	-2,021	4,082	-%
May 15, 2024	TWO SIGMA SECURITIES, LLC	sold off	-100	-6,952	-	-%
May 15, 2024	Tower Research Capital LLC (TRC)	added	0.4	-1,318	2,620	-%
May 15, 2024	BANK OF AMERICA CORP /DE/	sold off	-100	-34.00	-	-%
May 15, 2024	MORGAN STANLEY	reduced	-3.85	-37.00	64.00	-%
May 15, 2024	STATE STREET CORP	unchanged	-	-3,117	6,118	-%
May 13, 2024	GEODE CAPITAL MANAGEMENT, LLC	unchanged	-	-3,329	6,535	-%
May 13, 2024	UBS Group AG	new	-	1,441	1,441	-%
May 10, 2024	VANGUARD GROUP INC	reduced	-49.59	-22,019	11,041	-%

Are Funds Buying or Selling AVCO?

Are funds buying AVCO calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own AVCO

No. of Funds

Unveiling Avalon GloboCare Corp's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Jan 25, 2024	lu wenzhao	33.9%	3,733,788	SC 13D/A

Recent SEC filings of Avalon GloboCare Corp

View All Filings

Date Filed	Form Type	Document
May 15, 2024	NT 10-Q	NT 10-Q
May 07, 2024	8-K	Current Report
Apr 15, 2024	10-K	Annual Report
Apr 01, 2024	NT 10-K	NT 10-K
Mar 27, 2024	8-K	Current Report

Avalon GloboCare Corp News

Latest updates

Avalon GloboCare Corp Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

Income Statement (Quarterly)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2019Q3	2019Q2	2019Q1	2018Q4	2018Q3	2018Q2	2018Q1	2017Q4	2017Q3	2017Q2
Revenue	-	-	-	-	-	-	-	-	-	-	-	1,753,182	1,630,827	792,486	1,468,226	2,079,372	413,503	593,025	571,772	443,528	315,284	152,497
Gross Profit	-	-	-	-	-	44,189	97,853	168,700	75,085	72,880	130,084	189,161	53,228	79,892	10,007	412,497	-7,202	-17,281	-	32,188	44,867	-27,266
Costs and Expenses	-	-	-	-	-	252,138	236,349	318,064	-	-	324,473	135,821	329,988	319,835	274,157	289,248	295,481	362,749	226,794	215,366	227,755	287,085
Operating Expenses	-445.8%	-996,193	288,083	245,403	2,711,956	-741,700	2,360,844	2,133,671	2,377,365	2,376,468	3,168,526	3,379,719	5,529,575	4,423,644	4,475,320	2,779,273	2,497,440	1,346,598	1,395,838	-	-	-
S&GA Expenses	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	115	148	6,279
R&D Expenses	-Infinity%	-542	-	17,810	92,350	189,762	348,956	224,072	238,793	213,188	208,920	238,432	265,139	949,711	152,460	-	1,384	263	-	-	-	-
EBITDA Margin	-80.1%	-12.54	-6.96	-10.35	-10.01	-9.48	-4.49	-3.54	-3.13	-2.74	-2.51	-2.49	-	-	-	-	-	-	-	-	-	-
Interest Expenses	45.8%	334,186	229,144	10,267	2,021	90,081	-	-	-	-	-	-	2,356	8,822	25,697	157,635	25,205	1,300	408	244	122	210
Earnings Before Taxes	-554.8%	-9,724,921	-1,485,075	-2,543,313	-2,783,914	-2,417,681	-2,334,252	-2,024,219	-2,364,910	-2,367,118	-3,100,316	-3,251,959	-4,334,058	-4,438,823	-4,504,929	-2,754,261	-2,403,251	-1,343,815	-1,550,969	-	-	-
EBT Margin	-77.3%	-13.17	-7.43	-10.71	-10.40	-9.92	-4.68	-3.67	-3.24	-2.83	-2.59	-2.55	-	-	-	-	-	-	-	-	-	-
Net Income	-543.4%	-9,555,134	-1,485,075	-2,747,057	-2,919,744	-2,417,681	-2,334,252	-2,024,219	-2,364,910	-2,367,118	-3,100,316	-3,251,959	-4,334,058	-4,438,823	-4,504,929	-2,754,261	-2,403,251	-1,343,815	-1,550,969	-	-	-
Net Income Margin	-72.7%	-13.31	-7.70	-10.98	-10.51	-9.92	-4.68	-3.67	-3.24	-2.83	-2.59	-2.55	-	-	-	-	-	-	-	-	-	-
Free Cashflow	41.0%	-796,304	-1,348,613	-2,526,965	-1,854,995	-1,964,292	-1,717,012	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

Balance Sheet

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Balance Sheet																					(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Assets	-31.3%	20,583	29,967	30,231	30,836	19,752	12,911	10,275	9,669	10,242	10,394	10,378	11,285	10,366	11,156	10,759	10,348	10,491	10,669	13,633	12,729	13,396
Current Assets	-1.5%	851	864	1,423	1,391	2,374	4,449	1,653	914	1,323	1,258	1,325	2,164	1,286	2,153	1,832	1,348	1,571	1,807	3,992	2,923	3,625
Cash Equivalents	-16.5%	285	342	653	887	1,991	3,938	1,180	526	808	532	685	1,693	727	1,396	1,249	635	765	1,072	3,401	1,769	2,252
Inventory	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	13.00	17.00	13.00
Net PPE	-5.6%	38.00	40.00	117	140	138	214	266	321	362	400	443	440	479	501	520	555	601	625	375	399	250
Liabilities	0.5%	13,214	13,145	12,419	11,062	8,593	8,334	10,101	8,388	7,158	8,540	7,149	6,638	6,249	5,813	6,017	6,638	6,025	4,922	5,091	3,664	2,142
Current Liabilities	1.1%	6,763	6,692	5,965	5,176	3,580	3,328	7,210	5,148	4,402	4,536	3,680	3,224	2,592	2,439	2,627	3,033	2,835	4,332	1,035	2,664	1,142
Shareholder's Equity	-56.2%	7,369	16,823	17,812	19,775	11,159	4,577	174	1,281	3,084	1,854	3,229	4,647	4,117	5,343	4,742	3,710	4,465	5,747	7,842	9,065	11,254
Retained Earnings	-13.6%	-79,769	-70,214	-68,729	-65,982	-63,062	-60,645	-55,230	-53,202	-51,131	-48,797	-46,773	-44,408	-42,041	-38,941	-35,689	-32,632	-29,361	-25,431	-20,054	-15,697	-11,291
Additional Paid-In Capital	0.2%	67,885	67,781	67,277	66,481	65,950	65,372	56,119	55,153	54,889	51,336	50,688	49,756	46,856	45,029	41,216	37,131	34,593	31,984	30,376	26,426	24,153
Shares Outstanding	9.8%	11,000	10,014	10,448	10,164	9,962	9,704	8,893	8,850	8,846	8,536	8,402	8,341	8,228	-	-	-	-	-	-	-	-
Minority Interest	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-1,513	-1,042	-962	-862
Float	-	-	-	7,398	-	-	-	15,433	-	-	-	30,394	-	-	-	48,343	-	-	-	57,605	-	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Cashflow From Operations	41.0%	-796	-1,348	-2,524	-1,834	-1,964	-2,386	-2,175	-511	-1,716	-713	-1,078	-1,515	-1,360	-2,260	-1,926	-1,998	-1,761	-1,397	-2,497	-1,422	-855
Share Based Compensation	-34.6%	124	189	540	327	124	162	216	606	489	535	513	574	1,529	1,516	1,260	1,189	2,206	2,285	2,445	2,273	868
Cashflow From Investing	-60.0%	12*	30*	-2.02	-20.18	-8,998	1.00	-54.01	-1.75	-175*	-17.45	-19.67	-30.84	-140	-157*	-	-	-14.60	-387	-63.62	-87.37	-665
Cashflow From Financing	-29.7%	734	1,045	2,297	750	9,000	5,134	2,899	232	1,992	578	88.00	2,512	822	2,400	2,567	1,875	1,461	-410	4,104	1,000	-
Buy Backs	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

AVCO Income Statement

2023-12-31

Consolidated Statements of Operations and Comprehensive Loss - USD ($)	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
RENTAL REVENUE	$ 1,255,681	$ 1,202,169
OPERATING EXPENSES	1,017,493	929,441
OPERATING INCOME	238,188	272,728
LOSS FROM EQUITY METHOD INVESTMENT - LAB SERVICES MSO	(8,571,647)
OTHER OPERATING EXPENSES:
Advertising and marketing expenses	1,666,721	1,325,313
Professional fees	3,076,477	2,909,652
Compensation and related benefits	1,768,449	1,863,188
Research and development expenses	109,618	731,328
Litigation settlement		1,350,000
Other general and administrative expenses	798,959	886,142
Total Other Operating Expenses	7,420,224	9,065,623
LOSS FROM OPERATIONS	(15,753,683)	(8,792,895)
OTHER (EXPENSE) INCOME
Interest expense - amortization of debt discount and debt issuance cost	(544,010)	(3,310,684)
Interest expense - other	(773,780)	(185,751)
Conversion inducement expense		(344,264)
Loss from equity method investment - Epicon	(18,175)	(41,863)
Change in fair value of derivative liability	188,374	600,749
Impairment of equity method investment - Epicon	(454,679)
Gain on debts extinguishment	682,979
Other (expense) income	(324)	223,759
Total Other Expense, net	(953,327)	(3,137,952)
LOSS BEFORE INCOME TAXES	(16,707,010)	(11,930,847)
INCOME TAXES
NET LOSS	(16,707,010)	(11,930,847)
LESS: NET LOSS ATTRIBUTABLE TO NONCONTROLLING INTEREST
NET LOSS ATTRIBUTABLE TO AVALON GLOBOCARE CORP. COMMON SHAREHOLDERS	$ (16,707,010)	$ (11,930,847)
NET LOSS PER COMMON SHARE ATTRIBUTABLE TO AVALON GLOBOCARE CORP. COMMON SHAREHOLDERS:
Basic (in Dollars per share)	$ (1.59)	$ (1.28)
WEIGHTED AVERAGE COMMON SHARES OUTSTANDING:
Basic (in Shares)	10,528,975	9,328,609
COMPREHENSIVE LOSS:
NET LOSS	$ (16,707,010)	$ (11,930,847)
OTHER COMPREHENSIVE LOSS
Unrealized foreign currency translation loss	(18,590)	(47,871)
COMPREHENSIVE LOSS	(16,725,600)	(11,978,718)
LESS: COMPREHENSIVE LOSS ATTRIBUTABLE TO NONCONTROLLING INTEREST
COMPREHENSIVE LOSS ATTRIBUTABLE TO AVALON GLOBOCARE CORP. COMMON SHAREHOLDERS	(16,725,600)	(11,978,718)
Related Party
OTHER (EXPENSE) INCOME
Interest expense - related party	$ (33,712)	$ (79,898)

AVCO Balance Sheet

2023-12-31

Consolidated Balance Sheets - USD ($)	Dec. 31, 2023	Dec. 31, 2022
CURRENT ASSETS:
Cash	$ 285,400	$ 1,990,910
Rent receivable	197,473	134,626
Prepaid expense and other current assets	367,994	247,990
Total Current Assets	850,867	2,373,526
NON-CURRENT ASSETS:
Operating lease right-of-use assets, net	128,250	10,885
Property and equipment, net	38,083	138,294
Investment in real estate, net	7,191,404	7,360,087
Equity method investments, net	12,095,020	485,008
Advances for equity interest purchase		8,999,722
Other non-current assets	278,912	384,383
Total Non-current Assets	19,731,669	17,378,379
Total Assets	20,582,536	19,751,905
CURRENT LIABILITIES:
Accrued professional fees	1,804,100	1,673,411
Accrued research and development fees	208,772	838,001
Accrued payroll liability and compensation	588,722	223,722
Accrued litigation settlement	450,000	450,000
Accrued liabilities and other payables	272,915	283,234
Operating lease obligation	129,396	11,437
Equity method investment payable	666,667
Derivative liability	24,796
Convertible note payable, net	1,925,146
Total Current Liabilities	6,762,686	3,579,805
NON-CURRENT LIABILITIES:
Operating lease obligation - noncurrent portion	4,855
Accrued litigation settlement - noncurrent portion		450,000
Note payable, net	5,596,219	4,563,152
Total Non-current Liabilities	6,451,074	5,013,152
Total Liabilities	13,213,760	8,592,957
Commitments and Contingencies (Note 20)
EQUITY:
Common stock, $0.0001 par value; 490,000,000 shares authorized; 11,051,534 shares issued and 10,999,534 shares outstanding at December 31, 2023; 10,013,576 shares issued and 9,961,576 shares outstanding at December 31, 2022	1,105	1,005
Additional paid-in capital	67,885,051	65,949,723
Less: common stock held in treasury, at cost; 52,000 shares at December 31, 2023 and 2022	(522,500)	(522,500)
Accumulated deficit	(79,769,731)	(63,062,721)
Statutory reserve	6,578	6,578
Accumulated other comprehensive loss	(231,727)	(213,137)
Total Avalon GloboCare Corp. stockholders’ equity	7,368,776	11,158,948
Noncontrolling interest
Total Equity	7,368,776	11,158,948
Total Liabilities and Equity	20,582,536	19,751,905
Series A Convertible Preferred Stock
EQUITY:
Preferred stock, value	9,000,000	9,000,000
Series B Convertible Preferred Stock
EQUITY:
Preferred stock, value	11,000,000
Related Party
CURRENT LIABILITIES:
Accrued liabilities and other payables - related parties	206,458	100,000
Advance from sale of noncontrolling interest - related party	485,714
NON-CURRENT LIABILITIES:
Loan payable - related party	$ 850,000

About Avalon GloboCare Corp

WEBSITE	avalon-globocare.com

Avalon GloboCare Corp Frequently Asked Questions

What is the ticker symbol for Avalon GloboCare Corp? What does AVCO stand for in stocks?

AVCO is the stock ticker symbol of Avalon GloboCare Corp. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Avalon GloboCare Corp (AVCO)?

As of Fri May 17 2024, market cap of Avalon GloboCare Corp is 3.44 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of AVCO stock?

You can check AVCO's fair value in chart for subscribers.

What is the fair value of AVCO stock?

You can check AVCO's fair value in chart for subscribers. The fair value of Avalon GloboCare Corp is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Avalon GloboCare Corp is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for AVCO so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Avalon GloboCare Corp a good stock to buy?

The fair value guage provides a quick view whether AVCO is over valued or under valued. Whether Avalon GloboCare Corp is cheap or expensive depends on the assumptions which impact Avalon GloboCare Corp's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for AVCO.

What is Avalon GloboCare Corp's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri May 17 2024, AVCO's PE ratio (Price to Earnings) is -0.21 and Price to Sales (PS) ratio is 2.74. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. AVCO PE ratio will change depending on the future growth rate expectations of investors.